Oxymorphone Status

Oxymorphone Status

T is the second in a hoped-for series of Pain Medicine supplements that will deal with medications of interest to the pain medicine clinician. The first of these was in references to duloxetine [1]. The editors of Pain Medicine have decided to launch these supplements because research information about specific medications is often scattered among various journals and some early information may...

Bioequivalence of oxymorphone extended release and crush-resistant oxymorphone extended release

BACKGROUND A formulation of crush-resistant extended-release opioids may deter abuse. The purpose of this study was to evaluate the bioequivalence of oxymorphone extended-release (Oxy-ER) and a crush-resistant formulation of oxymorphone extended-release (Oxy-CRF). METHODS In three open-label, randomized studies, healthy adults at a clinical research center received two single oral doses of Ox...

Clinical Trial of Oxymorphone in Labour.

Concentration of oxymorphone in postmortem fluids and tissue.

Oxymorphone, a semi-synthetic opioid analgesic, has been available as Numorphan since the 1950s in the form of injectable solutions and a suppository. Recently, in 2006, oxymorphone was approved by the Federal Drug Administration for use in the form of immediate and extended release tablets under the trade name Opana. Since the advent of Opana, the number of deaths involving oxymorphone has ris...

Review of oral oxymorphone in the management of pain

Chronic cancer and nonmalignant pain (CNMP) is a common and major health problem afflicting approximately 40 million persons in the US. Most cancer patients, and many patients with CNMP, require opioid analgesics to obtain adequate pain relief. Oral oxymorphone is a new formulation of an existing parenteral opioid that has become available for the treatment of significant pain: acute postoperat...